Hemodynamic Classification
Forrester's Hemodynamic Subset Table 3 *Compelling reason for inotrope = SBP < 90, symptomatic hypotension, or worsening renal function. Table 4 ADHF Case #1 Q1 Hemodynamic Classification 
ADHF Drug Therapy

ADHF Guidelines: Diuretic Therapy
Recommended as an IV loop diuretic for patient admitted with fluid overload When response to diuretics is minimal, the following should be considered:
Fluid & sodium restriction, Fluid & sodium restriction, Initiation of increased doses or continuous infusion of loop diuretic, Addition of a second type of diuretic (metolazone or chlorothiazide), or Ultrafiltration
Page 2-170 - Table 4 ADHF Guidelines: Vasodilator Therapy
May be considered in addition to IV loop diuretics to rapidly improve symptoms in patients without symptomatic hypotension May be considered if persistent symptoms despite maximal loop diuretics and oral drug therapy p g p y When adjunctive therapy is required, IV vasodilators should be considered over inotropic drugs Table 4 ADHF Guidelines: Inotropic Therapy May be considered in patients with diminished peripheral perfusion or end-organ dysfunction, particularly if:
Marginal systolic blood pressure (< 90 mmHg), Symptomatic hypotension exists despite adequate filling Symptomatic hypotension exists despite adequate filling pressures, or Unresponsive to, or intolerant of, IV vasodilators May be considered in similar patients with fluid overload if they respond poorly to IV diuretics or have worsening renal function.
Page 2-170 - Table 4 Routine use of hemodynamic monitoring with invasive IV lines (e.g. pulmonary artery catheter) is not recommended Should be considered: Page 215 - Table 8 Adult Cardiac Arrest -pulseless VT, VF CPR / DCC Epinephrine 1 mg IV/IO Q3-5min
Vasopressin 40 units IV/IO x 1 (replaces first or second epinephrine dose)
Amiodarone 300mg IV/IO, repeat 150mg IV/IO x 1
If amiodarone is unavailable, lidocaine may be considered.
Lidocaine 1-1.5mg/kg IV/IO, repeat 0.5-0.75 mg/kg IV/IO q5-10min (max 3 mg/kg)
Page 2-178 - Table 10 Symptomatic Brady/Tachycardia Hypertensive Crises Patient Case#1 Q9 
Coronary Artery Disease
ACS Defined
Unstable angina (UA) Chest pain that often occurs at rest, can occur suddenly, may worsen suddenly, or may be stuttering in nature recurring over days to weeks. Diagnosis: ST-segment depression, T-wave inversion, or no ECG changes may occur, but no positive biomarkers for cardiac necrosis present
Non-ST-elevation MI (NSTEMI)
Symptoms similar to Unstable Angina but differentiated based on markers and EKG Diagnosis: Positive cardiac enzyme biomarkers of necrosis (troponin I or T elevation, CKMB fraction > 5%-10% of total CK), EKG-ST depression, T wave inversions, or Severe angina, ASA within 7 days, elevated markers, STsegment deviation >0.5 mm * HTN, DM, HLD, smoking, family history Score = 0-1 mortality 7%, Score = 2 mortality 8%, Score = 3 mortality 13%, Score = 4 mortality 20%, Score = 5 mortality 26%, Score = 6-7 mortality 41%
Page 2-201, Page 2-205, Table 9 Thrombolytics Table 11 UA/NSTEMI Case #1 
Peripheral Arterial Disease
Definition
A generic term that encompasses vascular insufficiencies due in non-coronary arteries secondary to atherosclerotic occlusions. The arteries affected supply blood flow to the brain, visceral organs, and limbs.
Affects approximately 27 million people affected by the disease. The incidence increases with age with approximately 20% of patients over 70 years affected. 
Symptoms
Treatment-Claudication
Cilostazol (Pletal) Mechanism of Action -a phosphodiesterase type 3 inhibitor that causes an increase in cyclic adenosine monophosphate. It has both vasodilatory and antiplatelet effects. Dose -100 mg orally twice daily Class I: to improve symptoms and increase walking distance Avoid use in patients with heart failure Pentoxifylline (Trental) Pentoxifylline (Trental)
Mechanism of Action -a methylxanthine derivative. Reduces blood and plasma viscosity, inhibit neutraphil adhesion and activation, increase erythrocyte and leukocyte deformality and lower plasma fibrinogen levels. 
Treatment Algorithm
Page 2-213, Figure 3 Treatment Algorithm Cont:
Page 2-214, Figure 4 Dyslipidemia Lipid and Lipoprotein Classification When selecting a statin, consider the percentage of LDL reduction needed.
(current LDL − goal LDL)/current LDL × 100 Select an initial dose to achieve an LDL reduction of 30%-40% if possible.
Outcomes data
Reduce major coronary events. Reduce CHD mortality. Reduce coronary procedures (percutaneous transluminal coronary angioplasty/coronary artery bypass graft Table 20 Bile Acid Sequestrants Step 2 Page Number 265 -Case #9
